Table 2.
The comparison of the clinical features of survivors and the non-survivors
| Survivors | Non-survivors | p-value | |
|---|---|---|---|
| Patients | 71 | 138 | |
| Age, years | 69.3 ± 10.2 | 73.8 ± 8.8 | 0.002 |
| Male | 56 (78.9) | 116 (84.1) | 0.352 |
| BMI, kg/m2 | 22.2 ± 3.9 | 22.3 ± 3.8 | 0.795 |
| Brinkman Index | |||
| 0/1–800/>800 | 26/14/25 | 42/31/46 | 0.719 |
| F, H-J Classification scale | |||
| 1/2/3/4/5 | 1/3/3/16/42 | 1/1/4/12/83 | 0.012 |
| Specialty hospital care | 60 (84.5) | 113 (81.9) | 0.634 |
| Ambulance transfer | 32 (45.1) | 69 (50.0) | 0.499 |
| Performing bronchoscopy | 14 (19.7) | 6 (4.4) | <0.001 |
| Treatment regimen use | |||
| Sivelestat | 37 (52.1) | 67 (48.9) | 0.626 |
| Diuretic drug | 37 (52.1) | 65 (47.1) | 0.492 |
| Anticoagulant therapy | 37 (52.1) | 50 (36.2) | 0.027 |
| Immunosuppressive therapy | 30 (42.3) | 45 (32.6) | 0.169 |
| Intravenous high-dose cyclophosphamide | 9 (12.7) | 23 (16.7) | 0.448 |
| PMX | 4 (5.6) | 9 (6.5) | 0.801 |
| Recombinant human soluble thrombomodulin | 3 (4.2) | 6 (4.4) | 0.967 |
| Antibiotic therapy | 71 (100) | 135 (97.8) | 0.211 |
| β-Lactams | 60 (84.5) | 116 (84.1) | 0.933 |
| Co-trimoxazole | 56 (78.9) | 59 (42.8) | <0.001 |
| Quinolones | 38 (53.5) | 65 (47.1) | 0.379 |
| Macrolides | 23 (32.4) | 25 (18.1) | 0.020 |
| Tetracycline | 6 (8.5) | 12 (8.7) | 0.952 |
| Anti-MRSA antibiotics | 6 (8.5) | 11 (7.8) | 0.904 |
| Clindamycin | 3 (4.2) | 2 (1.5) | 0.214 |
| Aminoglycoside | 2 (2.8) | 1 (0.7) | 0.228 |
| Others | 5 (7.0) | 7 (5.1) | 0.562 |
Data are presented as mean ± SD or n (%), unless otherwise indicated. Definition of abbreviations: BMI = Body Mass Index, F, H-J = Fletcher, Hugh-Jones, PMX = Direct hemoperfusion with polymyxin B-immobilized fiber, MRSA = Methicillin-resistant Staphylococcus aureus. The total dose was not equal to 209 because there were missing values in the data file